An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2010
This article has no abstract
Epistemonikos ID: 29b064ca126c43c7ebe54c6dceeeebdf91a968d3
First added on: Jun 12, 2019